AJ Lanigan: Yes. In Reality, pharma businesses are building significant cash with therapies like Keytruda and Opdivo that offer with PD-1 and PD-L1. Here’s the super interesting element: consider checkpoints as traffic indicators. You don’t want an immune system that’s managing wild similar to a freight practice above a cliff. waiting for link from Social Bookmarking